123 related articles for article (PubMed ID: 37967116)
21. VicTORia: a randomised phase II study to compare vinorelbine in combination with the mTOR inhibitor everolimus versus vinorelbine monotherapy for second-line chemotherapy in advanced HER2-negative breast cancer.
Decker T; Marschner N; Muendlein A; Welt A; Hagen V; Rauh J; Schröder H; Jaehnig P; Potthoff K; Lerchenmüller C
Breast Cancer Res Treat; 2019 Aug; 176(3):637-647. PubMed ID: 31115844
[TBL] [Abstract][Full Text] [Related]
22. Trabectedin in combination with doxorubicin for first-line treatment of advanced uterine or soft-tissue leiomyosarcoma (LMS-02): a non-randomised, multicentre, phase 2 trial.
Pautier P; Floquet A; Chevreau C; Penel N; Guillemet C; Delcambre C; Cupissol D; Selle F; Isambert N; Piperno-Neumann S; Thyss A; Bertucci F; Bompas E; Alexandre J; Collard O; Lavau-Denes S; Soulié P; Toulmonde M; Le Cesne A; Lacas B; Duffaud F;
Lancet Oncol; 2015 Apr; 16(4):457-64. PubMed ID: 25795402
[TBL] [Abstract][Full Text] [Related]
23. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial.
Tripathy D; Im SA; Colleoni M; Franke F; Bardia A; Harbeck N; Hurvitz SA; Chow L; Sohn J; Lee KS; Campos-Gomez S; Villanueva Vazquez R; Jung KH; Babu KG; Wheatley-Price P; De Laurentiis M; Im YH; Kuemmel S; El-Saghir N; Liu MC; Carlson G; Hughes G; Diaz-Padilla I; Germa C; Hirawat S; Lu YS
Lancet Oncol; 2018 Jul; 19(7):904-915. PubMed ID: 29804902
[TBL] [Abstract][Full Text] [Related]
24. A phase Ib study of combined VEGFR and mTOR inhibition with vatalanib and everolimus in patients with advanced renal cell carcinoma.
Bitting RL; Healy P; Creel PA; Turnbull J; Morris K; Wood SY; Hurwitz HI; Starr MD; Nixon AB; Armstrong AJ; George DJ
Clin Genitourin Cancer; 2014 Aug; 12(4):241-50. PubMed ID: 24685058
[TBL] [Abstract][Full Text] [Related]
25. Ribociclib with letrozole vs letrozole alone in elderly patients with hormone receptor-positive, HER2-negative breast cancer in the randomized MONALEESA-2 trial.
Sonke GS; Hart LL; Campone M; Erdkamp F; Janni W; Verma S; Villanueva C; Jakobsen E; Alba E; Wist E; Favret AM; Bachelot T; Hegg R; Wheatley-Price P; Souami F; Sutradhar S; Miller M; Germa C; Burris HA
Breast Cancer Res Treat; 2018 Feb; 167(3):659-669. PubMed ID: 29058175
[TBL] [Abstract][Full Text] [Related]
26. A Phase Ib/II Study of the CDK4/6 Inhibitor Ribociclib in Combination with Docetaxel plus Prednisone in Metastatic Castration-Resistant Prostate Cancer.
de Kouchkovsky I; Rao A; Carneiro BA; Zhang L; Lewis C; Phone A; Small EJ; Friedlander T; Fong L; Paris PL; Ryan CJ; Szmulewitz RZ; Aggarwal R
Clin Cancer Res; 2022 Apr; 28(8):1531-1539. PubMed ID: 35176163
[TBL] [Abstract][Full Text] [Related]
27. Phase Ib/II study of ceritinib in combination with ribociclib in patients with ALK-rearranged non-small cell lung cancer.
Santoro A; Su WC; Navarro A; Simonelli M; Ch Yang J; Ardizzoni A; Barlesi F; Hyoung Kang J; DiDominick S; Abdelhady A; Chen X; Stammberger U; Felip E
Lung Cancer; 2022 Apr; 166():170-177. PubMed ID: 35298959
[TBL] [Abstract][Full Text] [Related]
28. A Phase 0 Trial of Ribociclib in Recurrent Glioblastoma Patients Incorporating a Tumor Pharmacodynamic- and Pharmacokinetic-Guided Expansion Cohort.
Tien AC; Li J; Bao X; Derogatis A; Kim S; Mehta S; Sanai N
Clin Cancer Res; 2019 Oct; 25(19):5777-5786. PubMed ID: 31285369
[TBL] [Abstract][Full Text] [Related]
29. Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial.
Schöffski P; Chawla S; Maki RG; Italiano A; Gelderblom H; Choy E; Grignani G; Camargo V; Bauer S; Rha SY; Blay JY; Hohenberger P; D'Adamo D; Guo M; Chmielowski B; Le Cesne A; Demetri GD; Patel SR
Lancet; 2016 Apr; 387(10028):1629-37. PubMed ID: 26874885
[TBL] [Abstract][Full Text] [Related]
30. Efficacy of trabectedin in advanced soft tissue sarcoma: beyond lipo- and leiomyosarcoma.
De Sanctis R; Marrari A; Marchetti S; Mussi C; Balzarini L; Lutman FR; Daolio P; Bastoni S; Bertuzzi AF; Quagliuolo V; Santoro A
Drug Des Devel Ther; 2015; 9():5785-91. PubMed ID: 26604682
[TBL] [Abstract][Full Text] [Related]
31. Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer.
Hortobagyi GN; Stemmer SM; Burris HA; Yap YS; Sonke GS; Paluch-Shimon S; Campone M; Petrakova K; Blackwell KL; Winer EP; Janni W; Verma S; Conte P; Arteaga CL; Cameron DA; Mondal S; Su F; Miller M; Elmeliegy M; Germa C; O'Shaughnessy J
Ann Oncol; 2018 Jul; 29(7):1541-1547. PubMed ID: 29718092
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules.
Demetri GD; Chawla SP; von Mehren M; Ritch P; Baker LH; Blay JY; Hande KR; Keohan ML; Samuels BL; Schuetze S; Lebedinsky C; Elsayed YA; Izquierdo MA; Gómez J; Park YC; Le Cesne A
J Clin Oncol; 2009 Sep; 27(25):4188-96. PubMed ID: 19652065
[TBL] [Abstract][Full Text] [Related]
33. A Phase II Open Label Study of Everolimus in Combination With Endocrine Therapy in Resistant Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer.
Yardley DA; Liggett W; Mainwaring M; Castrellon A; Blakely L; Hemphill B; Anz B; Young RR; Shastry M; DeBusk LM; Hainsworth JD; Burris HA
Clin Breast Cancer; 2020 Apr; 20(2):89-97. PubMed ID: 31932237
[TBL] [Abstract][Full Text] [Related]
34. Phase 2 study of anastrozole in rare cohorts of patients with estrogen receptor/progesterone receptor positive leiomyosarcomas and carcinosarcomas of the uterine corpus: The PARAGON trial (ANZGOG 0903).
Edmondson RJ; O'Connell RL; Banerjee S; Mileshkin L; Sykes P; Beale P; Fisher A; Bonaventura A; Millan D; Nottley S; Benson C; Hamilton A; Sjoquist K; Alexander L; Kelly C; Carty K; Divers L; Bradshaw N; Friedlander M;
Gynecol Oncol; 2021 Dec; 163(3):524-530. PubMed ID: 34625284
[TBL] [Abstract][Full Text] [Related]
35. Everolimus in patients with multiply relapsed or cisplatin refractory germ cell tumors: results of a phase II, single-arm, open-label multicenter trial (RADIT) of the German Testicular Cancer Study Group.
Fenner M; Oing C; Dieing A; Gauler T; Oechsle K; Lorch A; Hentrich M; Kopp HG; Bokemeyer C; Honecker F
J Cancer Res Clin Oncol; 2019 Mar; 145(3):717-723. PubMed ID: 30232558
[TBL] [Abstract][Full Text] [Related]
36. Ribociclib Plus Trastuzumab in Advanced HER2-Positive Breast Cancer: Results of a Phase 1b/2 Trial.
Goel S; Pernas S; Tan-Wasielewski Z; Barry WT; Bardia A; Rees R; Andrews C; Tahara RK; Trippa L; Mayer EL; Winer EP; Spring LM; Tolaney SM
Clin Breast Cancer; 2019 Dec; 19(6):399-404. PubMed ID: 31235441
[TBL] [Abstract][Full Text] [Related]
37. Phase Ib Study of Ribociclib plus Fulvestrant and Ribociclib plus Fulvestrant plus PI3K Inhibitor (Alpelisib or Buparlisib) for HR
Tolaney SM; Im YH; Calvo E; Lu YS; Hamilton E; Forero-Torres A; Bachelot T; Maur M; Fasolo A; Tiedt R; Nardi L; Stammberger U; Abdelhady AM; Ruan S; Lee SC
Clin Cancer Res; 2021 Jan; 27(2):418-428. PubMed ID: 32887722
[TBL] [Abstract][Full Text] [Related]
38. Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2- advanced breast cancer in the randomized MONALEESA-2 trial.
O'Shaughnessy J; Petrakova K; Sonke GS; Conte P; Arteaga CL; Cameron DA; Hart LL; Villanueva C; Jakobsen E; Beck JT; Lindquist D; Souami F; Mondal S; Germa C; Hortobagyi GN
Breast Cancer Res Treat; 2018 Feb; 168(1):127-134. PubMed ID: 29164421
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial.
Demetri GD; von Mehren M; Jones RL; Hensley ML; Schuetze SM; Staddon A; Milhem M; Elias A; Ganjoo K; Tawbi H; Van Tine BA; Spira A; Dean A; Khokhar NZ; Park YC; Knoblauch RE; Parekh TV; Maki RG; Patel SR
J Clin Oncol; 2016 Mar; 34(8):786-93. PubMed ID: 26371143
[TBL] [Abstract][Full Text] [Related]
40. The Novel Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) Alone and in Dual-Targeting Approaches Demonstrates Antitumoral Efficacy in Neuroendocrine Tumors in vitro.
Aristizabal Prada ET; Nölting S; Spoettl G; Maurer J; Auernhammer CJ
Neuroendocrinology; 2018; 106(1):58-73. PubMed ID: 28226315
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]